Evidence map›Paper›PMID 36560514›Full record

ArticleVaccines2022

COVID-19 and Pulmonary Embolism Outcomes among Hospitalized Patients in the United States: A Propensity-Matched Analysis of National Inpatient Sample.

Adeel Nasrullah, Karthik Gangu, Nichole B Shumway, Harmon R Cannon, Ishan Garg, Hina Shuja, Aniesh Bobba, Prabal Chourasia, Abu Baker Sheikh, Rahul Shekhar

Abstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Impact of atrial fibrillation on pulmonary embolism hospitalization: Nationwide analysis.American heart journal plus : cardiology research and practice · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adeel NasrullahDivision of Pulmonology and Critical Care, Allegheny Health Network, Pittsburg, PA 15212, USA.
Karthik GanguDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Nichole B ShumwayDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.
Harmon R CannonDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.
Ishan GargDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.
Hina ShujaDepartment of Medicine, Karachi Medical and Dental College, Karachi 74700, Pakistan.
Aniesh BobbaDepartment of Medicine, John H Stronger Hospital, Cook County, Chicago, IL 60612, USA.ORCID 0000-0002-9932-9345
Prabal ChourasiaDepartment of Medicine, Mary Washington Hospital, Fredericksburg, VA 22401, USA.
Abu Baker SheikhDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.ORCID 0000-0003-0503-6961
Rahul ShekharDepartment of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87106, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Venous thromboembolism, in particular, pulmonary embolism (PE), is a significant contributor to the morbidity and mortality associated with COVID-19. In this study, we utilized the National Inpatient Sample (NIS) database 2020 to evaluate and compare clinical outcomes in patients with COVID-19 with and without PE. Our sample includes 1,659,040 patients hospitalized with COVID-19 pneumonia between January 2020 and December 2020. We performed propensity-matched analysis for patient characteristics and in-hospital outcomes, including the patient’s age, race, sex, insurance status, median income, length of stay, mortality, hospitalization cost, comorbidities, mechanical ventilation, and vasopressor support. Patients with COVID-19 with PE had a higher need for mechanical ventilation (25.7% vs. 15.6%, adjusted odds ratio 1.4, 95% CI 1.4−1.5, p < 0.001), the vasopressor requirement (5.4% vs. 2.6%, adjusted OR 1.6, 95% CI 1.4−1.8, p < 0.001), longer hospital stays (10.8 vs. 7.9 days, p < 0.001), and overall higher in-hospital mortality (19.1 vs. 13.9%, adjusted OR of 1.3, 95% CI 1.1−1.5, p < 0.001). This study highlights the need for more aggressive management of PE in COVID-19-positive patients with the aim to improve early diagnosis and treatment to reduce morbidity, mortality, and healthcare costs seen in the synchronous COVID-19 and PE-positive patients.

Indexed as

COVID-19National Inpatient Samplepulmonary embolismvenous thromboembolism

Identifiers

PMID36560514
PMCPMC9784895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.